The Company’s AI Platform is Now Being Deployed Across 23 Therapeutic Areas, including Oncology, Immunology, Cardiometabolic Diseases, and Gastroenterology

QuantHealth, the AI-powered clinical simulation company, today announced it has successfully simulated the results from over 350 clinical trials, achieving up to 90 percent predictive accuracy and delivering measurable impact across a range of development programs. The company’s technology is now being deployed across 23 therapeutic areas, including oncology, immunology, cardiometabolic diseases, and gastroenterology, enabling drug developers to optimize trial design, accelerate timelines, and prioritize assets with greater confidence.

In one case, a top-10 global pharmaceutical company utilized QuantHealth’s simulation engine to evaluate a Phase II trial for a first-in-class autoimmune therapy. QuantHealth’s simulation identified a likely non-responder subgroup that could have diluted and weakened the trial’s results. Based on this information, the pharmaceutical company redesigned the protocol to focus on a refined patient population, resulting in a 15-month reduction in enrollment time, a $31.4 million savings in trial costs, and a 2.8 times increase in the predicted probability of success.

“By giving R&D teams a clearer understanding of how trials are going to perform before they begin, we're helping them make smarter, more informed decisions,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “The ability to identify what works early on not only reduces the risk of failure, but also leads to major cost savings and reduced timelines. This kind of predictive insight is particularly impactful in advancing innovative assets, where every day and every dollar counts and optimizing outcomes is critical to success.”

QuantHealth’s predictive capabilities also extend to the most challenging areas of drug development, including first-in-class (FIC) programs and Phase II trials. FIC programs carry some of the highest failure rates in drug development due to the limited prior data available to guide development, with only 8 percent of 2023–2024 submissions achieving regulatory approval. Among the 350 trials simulated by QuantHealth’s technology, 110 were for FIC drugs and therapies. In Phase II, where industry success rates typically fall below 30 percent, QuantHealth performed 168 simulations, supporting smarter trial design and reducing risk in clinical trials. Third-party validations of QuantHealth’s AI platform are currently underway with pharmaceutical partners and through external peer review.

“First-in-class assets are where the uncertainty is highest, and the stakes are greatest,” said Brigham Hyde, CEO and Co-founder of Atropos Health. “Through our Evidence™ Network, QuantHealth is able to leverage high-quality real-world data in a way that supports rigorous simulation where better predictions can help teams confidently advance transformative therapies and bring hope to patients in the most underserved disease areas”.

This news follows the launch of QuantHealth's Large Real-World Drug Model (LRDM v1.0), a first-of-its-kind clinical trial foundation model representing an industry breakthrough in using AI to predict drug effectiveness and patient outcomes. LRDM is continuously updated with new capabilities and will be expanded in version 1.1 later this year. QuantHealth continues this momentum by expanding its industry partnerships and growing the number of drugs simulated on its platform, helping pharmaceutical companies bring better therapies to market faster.

About QuantHealth: QuantHealth is an AI-powered drug development platform that simulates how individual patients may respond to treatments, enabling pharmaceutical companies to predict full clinical trial outcomes with up to 90 percent accuracy before trials even begin. Powered by a proprietary engine trained on real-world data from more than 350 million patients and 100,000 therapeutics, the platform equips pharmaceutical research & development teams with the insights they need to make faster, smarter decisions on trial go/no-go calls, cohort and protocol design, drug repurposing, indication expansion, and first-in-class development strategies. Founded by healthcare experts and backed by top-tier life sciences investors, QuantHealth partners with leading pharmaceutical companies to fundamentally reshape how clinical trials are designed and executed. To learn more, visit https://quanthealth.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722764714/en/